Clinical Trial Update: Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Yttrium-90 anti-CD45 monoclonal antibody BC8 followed by donor stem cell transplant in patients with high-risk AML, ALL, or MD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Donor stem cell transplant
• Yttrium-90 anti-CD45 monoclonal antibody BC8 (Yttrium-90 anti-CD45 monoclonal antibody BC8)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2019-01-25